Literature DB >> 19829244

Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.

Uday M Pawar1, Vishal Kundnani, Vikas Agashe, Amita Nene, Abhay Nene.   

Abstract

STUDY
DESIGN: Prospective cohort study.
OBJECTIVE: We report the first study of multidrug-resistant tuberculosis (MDR-TB) in the spine. The aim was to determine the clinical, radiologic, and drug resistance profile as well as the factors associated with treatment outcome of MDR-TB in the spine. SUMMARY OF BACKGROUND DATA: Tuberculosis of the spine is the most common extrapulmonary form of tuberculosis in the Asian subcontinent. The disease in few cases is resistant to the primary anti-Koch's medications and the number of cases detected is on the rise. Multidrug resistant form of tuberculosis of the spine is ill reported in the literature. The diagnosis, management thus remains a challenge to the treating surgeon. This study tries to assess these critical issues of this "new" disease.
METHODS: Described here are the clinical characteristics of 25 MDR-TB spine patients identified in the study and their drug susceptibility patterns. They were followed up clinically, radiologically after a biopsy, culture, and Drug Susceptibility Testing. According to their Drug Susceptibility Testing pattern and previous history of Anti-Tubercular Treatment (ATT), individualized treatment regimens were tailored for each patient by an expert physician.
RESULTS: Majority of the patients seen in the present study were in the productive years of their life. (Males (9) mean age: 38.5 years and females (16) mean age: 34.3 years. Four patients were defaulters of the ATT. The average number of drugs used was 6, including 4 second line drugs. Average treatment duration was 24 months. Almost 50% of the patients had adverse drug effects. Of the 25 patients, 19 achieved healed status and 6 are still on treatment. Four patients required surgery for mechanical instability of the spine. Radiologic improvement was observed in all the cases after a mean treatment of 6 months. Five predictors were identified for successful outcome of MDR-TB. They include progressive clinical improvement at 6 months, radiologic improvement during treatment and disease with Mycobacterium tuberculosis strains exhibiting resistance to less than or up to 3 antitubercular drugs, use of less than or up to 4 second-line drugs in treatment, and no change of regimen during treatment.
CONCLUSION: MDR-TB of the spine is a different disease and is here to stay. There is an urgent need to include culture and drug susceptibility testing in the protocol for the treatment of tuberculosis of the spine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19829244     DOI: 10.1097/BRS.0b013e3181af7797

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  25 in total

1.  Drug resistance patterns in 111 cases of drug-resistant tuberculosis spine.

Authors:  Kapil Mohan; Saurabh Rawall; Uday M Pawar; Meeta Sadani; Premik Nagad; Amita Nene; Abhay Nene
Journal:  Eur Spine J       Date:  2012-01-20       Impact factor: 3.134

2.  Management of drug-resistant spinal tuberculosis with a combination of surgery and individualised chemotherapy: a retrospective analysis of thirty-five patients.

Authors:  Litao Li; Zehua Zhang; Fei Luo; Jianzhong Xu; Peng Cheng; Zheng Wu; Qiang Zhou; Qingyi He; Fei Dai; Jian Wang; Jinsong Zhang
Journal:  Int Orthop       Date:  2011-11-09       Impact factor: 3.075

Review 3.  Establishing the diagnosis of tuberculous vertebral osteomyelitis.

Authors:  Juan D Colmenero; Juan D Ruiz-Mesa; Rocío Sanjuan-Jimenez; Beatriz Sobrino; Pilar Morata
Journal:  Eur Spine J       Date:  2012-05-11       Impact factor: 3.134

4.  Revision surgery for spinal tuberculosis with secondary deformity after treatment with debridement, instrumentation, and fusion.

Authors:  Tingxian Ling; Limin Liu; Xi Yang; Zhe Qiang; Xinxing Hu; Yonggang An
Journal:  Eur Spine J       Date:  2014-12-27       Impact factor: 3.134

Review 5.  Spinal tuberculosis: a review.

Authors:  Ravindra Kumar Garg; Dilip Singh Somvanshi
Journal:  J Spinal Cord Med       Date:  2011       Impact factor: 1.985

6.  Hesperidin methyl chalcone alleviates spinal tuberculosis in New Zealand white rabbits by suppressing immune responses.

Authors:  Yi Zhao; Yong Jiao; Lei Wang
Journal:  J Spinal Cord Med       Date:  2018-08-20       Impact factor: 1.985

7.  Primary extrapulmonary multidrug-resistant tuberculosis in an immunocompetent child presenting with pleural effusion.

Authors:  Sankalp Yadav; Gautam Rawal
Journal:  Transl Pediatr       Date:  2017-01

8.  Pre-extensively drug-resistant tuberculosis spondylodiscitis in an immunocompetent patient: a case report.

Authors:  Safaa Fellous; Hanan Rkain; Latifa Tahiri; Amina Bouraqadi; Ittimad Nassar; Fadoua Allali
Journal:  Pan Afr Med J       Date:  2020-07-08

9.  Drug susceptibility testing guided treatment for drug-resistant spinal tuberculosis: a retrospective analysis of 19 patients.

Authors:  Lan Xu; Xu Jian-Zhong; Liu Xue-Mei; Ge Bao-Feng
Journal:  Int Surg       Date:  2013 Apr-Jun

10.  Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.

Authors:  J Arockiaraj; G S Balaji; V M Cherian; Jepegnanam T S; B P Thomas; Joy S Michael; P M Poonnoose
Journal:  J Clin Orthop Trauma       Date:  2017-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.